Answers are grounded in this paper and cite their sources.
Retrospective study demonstrates high remission rates and rapid MRD negativity with low-dose decitabine and venetoclax in AML, indicating an effective option for unfit patients.
The combination of hypomethylating agents and venetoclax (VEN) has emerged as a new standard of care for elderly or unfit patients. In this study, we conducted a retrospective analysis of 37 patients with acute myeloid leukemia (AML) to investigate the efficacy and safety of a low‑dose 10‑day decitabine (DEC) combined with venetoclax (VEN) regimen (DEC 6 mg/m 2 for 10 days and VEN for 14 days). The composite complete remission (CRc) rate was 78.4%, with 88.9% in favorable group and 75.0% in intermediate/adverse group according to ELN-2022 risk stratification. Among patients who achieved CRc, 79.3% patients attained MRD negativity after the first cycle. With a median follow-up of 40.0 months, the median overall survival (OS) was 36.1 months. The 36-month OS and EFS rates were 35.0% and 40.4%. Hematologic toxicities were the most common adverse events. The multivariate analysis showed that patients with ECOG < 3 and non-complex karyotype had significantly better OS. The regimen of low-dose 10-day DEC plus VEN induced rapid MRD negativity with good tolerability, along with high long-term survival in patient ineligible for intensive therapy.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: